Cheryl Fitzer-Attas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6563080/publications.pdf

Version: 2024-02-01

34 papers	2,549 citations	304743 22 h-index	434195 31 g-index
35 all docs	35 docs citations	35 times ranked	3296 citing authors

#	Article	IF	Citations
1	A Critical Role for Syk in Signal Transduction and Phagocytosis Mediated by FcÎ³ Receptors on Macrophages. Journal of Experimental Medicine, 1997, 186, 1027-1039.	8.5	471
2	FcÎ³ Receptorâ€“Mediated Phagocytosis in Macrophages Lacking the Src Family Tyrosine Kinases Hck, Fgr, and Lyn. Journal of Experimental Medicine, 2000, 191, 669-682.	8.5	255
3	Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). Npj Digital Medicine, 2020, 3, 55.	10.9	236
4	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurology, The, 2011, 10, 415-423.	10.2	192
5	An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid-Î² Derivatives. Journal of Neuroscience, 2004, 24, 6277-6282.	3.6	162
6	Data Analytics from Enrollâ€<scp>HD</scp>, a Global Clinical Research Platform for Huntington's Disease. Movement Disorders Clinical Practice, 2017, 4, 212-224.	1.5	137
7	Longâ€term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Movement Disorders, 2009, 24, 564-573.	3.9	126
8	The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids. Carcinogenesis, 1987, 8, 217-220.	2.8	108
9	Increased Melanoma Risk in Parkinson Disease. Archives of Neurology, 2010, 67, 347.	4.5	101
10	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 145-152.	10.2	90
11	Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology, 2009, 72, S32-8.	1.1	78
12	The T-body approach: potential for cancer immunotherapy. Seminars in Immunopathology, 1996, 18, 199-209.	4.0	73
13	HDâ€CAB: A cognitive assessment battery for clinical trials in Huntington's disease^{1,2,3}. Movement Disorders, 2014, 29, 1281-1288.	3.9	73
14	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinsonâ€™s disease: a pharmacogenetic study. Brain, 2016, 139, 2050-2062.	7.6	53
15	Longâ€term effects of rasagiline and the natural history of treated Parkinson's disease. Movement Disorders, 2016, 31, 1489-1496.	3.9	45
16	Studies on Protein Kinase C and Colon Carcinogenesis. Archives of Surgery, 1987, 122, 1475.	2.2	42
17	Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem. Nature Reviews Drug Discovery, 2017, 16, 736-736.	46.4	34
18	Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease. PLoS ONE, 2013, 8, e60691.	2.5	33

#	Article	IF	Citations
19	Direct T Cell Activation by Chimeric Single Chain Fv-Syk Promotes Syk-Cbl Association and Cbl Phosphorylation. Journal of Biological Chemistry, 1997, 272, 8551-8557.	3.4	31
20	Long-Term Efficacy of Rasagiline in Early Parkinson's Disease. International Journal of Neuroscience, 2010, 120, 404-408.	1.6	29
21	High prevalence of malignant melanoma in Israeli patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2011, 118, 1199-1207.	2.8	28
22	Fitâ€forâ€Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience. Clinical and Translational Science, 2021, 14, 62-74.	3.1	28
23	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. Movement Disorders, 2020, 35, 606-615.	3.9	25
24	Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D 2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18 F-MNI-659 and 11 C-raclopride with correction for partial volume effect. NeuroImage, 2017, 152, 330-339.	4.2	24
25	Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective. Movement Disorders, 2012, 27, 651-655.	3.9	20
26	Expression of functionally intact pdgf-Î± receptors in highly metastatic 3ll lewis lung carcinoma cells. International Journal of Cancer, 1993, 53, 315-322.	5.1	14
27	Tyrosine kinase chimeras for antigen-selective T-body therapy. Advanced Drug Delivery Reviews, 1998, 31, 171-182.	13.7	14
28	Revisiting the Logan plot to account for non-negligible blood volume in brain tissue. EJNMMI Research, 2017, 7, 66.	2.5	8
29	Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects. Frontiers in Neurology, 2021, 12, 595679.	2.4	6
30	The expression of PDGF-Î± but not PDGF-Î² receptors is suppressed in Swiss/3T3 fibroblasts over-expressing protein kinase C-Î±. FEBS Letters, 1994, 342, 165-170.	2.8	5
31	Toward <scp>eâ€Scales</scp>: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. Movement Disorders Clinical Practice, 2021, 8, 208-214.	1.5	5
32	The Role of Platelet Derived Growth Factor (PDGF) and Its Receptors in Cancer and Metastasis. , 2001, , 167-186.		0
33	[P4â€“162]: LANDSCAPE ANALYSIS OF BIOMETRIC MONITORING DEVICES (BMDS) UTILIZED IN ASSESSING COGNITION, SLEEP AND MOBILITY IN ALZHEIMER's DISEASE AND OTHER AGEâ€RELATED NEUROLOGICAL DISEASES. Alzheimer's and Dementia, 2017, 13, P1322.	0.8	0
34	Genes and Antigens Controlling Tumor Metastasis. Contributions To Oncology / Beitrage Zur Onkologie, 1992, , 1-12.	0.1	0